Kidney function in acromegaly.
Creatinine clearance and daily urinary albumin and beta2-microglobulin excretion rates (radio-immunoassays) were measured several times in 14 patients with acromegaly. Eleven patients were treated with bromocriptine, 5 to 55 mg/day. The activity of the disease was assessed by measuring urinary growth hormone excretion (radio-immunoassay). In agreement with previous investigations we found the creatinine clearance elevated. However, no correlation was found between this variable and urinary growth hormone excretion. Urinary albumin and beta 2-microglobulin excretion rates were not significantly different from our previous results in 27 adults control subjects. There was no correlation between urinary growth hormone excretion and urinary albumin or beta 2-microglobulin excretion rates. Bromocriptine treatment reduced urinary growth hormone excretion from 220 to 91 ng/24 hours, p less than 0.01, but no significant alterations were induced in the above mentioned kidney function variables.
D000172:Acromegaly / Q000188:drug therapy / Q000503:physiopathology* / Q000652:urine; D000328:Adult; D000368:Aged; D000419:Albuminuria; D001971:Bromocriptine / Q000627:therapeutic use; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005919:Glomerular Filtration Rate; D013006:Growth Hormone / Q000652:urine; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D001613:beta 2-Microglobulin / Q000652:urine
D001613:beta 2-Microglobulin; D001971:Bromocriptine; D013006:Growth Hormone; D003404:Creatinine